{"DataElement":{"publicId":"3607893","version":"1","preferredName":"Clinical Study Protocol Blinded Agent Administered Course Type","preferredDefinition":"the type of protocol-defined administration of a blinded agent.","longName":"PROT_BLIND_AGT_ADM_CRSE_TYP","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3607890","version":"1","preferredName":"Clinical Study Protocol Blinded Agent Administered","preferredDefinition":"information related to the protocol-defined administration of a blinded agent.","longName":"PROT_BLIND_AGT_ADM","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"3607888","version":"1","preferredName":"Clinical Study Protocol Blinded Agent","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.:Describes an experiment or clinical trial in which patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25320:C49068:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blinded","conceptCode":"C49068","definition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA311A1-E373-6FAA-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-09","modifiedBy":"ONEDATA","dateModified":"2012-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA311A1-E381-6FAA-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3533990","version":"1","preferredName":"Course Type","preferredDefinition":"the cycle of protocol-defined regimen being administered.","longName":"3533990v1.0","context":"NRG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Maintenance Ipilimumab/placebo (cycle 6)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 6)","ValueMeaning":{"publicId":"3597205","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 6)","longName":"3597205","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 6)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DEA3-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DEBC-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Maintenance Ipilimumab/placebo (cycle 5)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 5)","ValueMeaning":{"publicId":"3597206","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 5)","longName":"3597206","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DEC6-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DEDF-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Maintenance Ipilimumab/placebo (cycle 4)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 4)","ValueMeaning":{"publicId":"3597207","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 4)","longName":"3597207","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DEE9-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DF02-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Maintenance Ipilimumab/placebo (cycle 3)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 3)","ValueMeaning":{"publicId":"3597208","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 3)","longName":"3597208","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DF0C-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DF25-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Maintenance Ipilimumab/placebo (cycle 2)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 2)","ValueMeaning":{"publicId":"3597209","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 2)","longName":"3597209","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DF2F-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DF48-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Maintenance Ipilimumab/placebo (cycle 1)","valueDescription":"Maintenance Ipilimumab/placebo (cycle 1)","ValueMeaning":{"publicId":"3597210","version":"1","preferredName":"Maintenance Ipilimumab/placebo (cycle 1)","longName":"3597210","preferredDefinition":"Maintenance Ipilimumab/placebo (cycle 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DF52-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DF6B-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 6)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 6)","ValueMeaning":{"publicId":"3597211","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 6)","longName":"3597211","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 6)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DF75-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DF8E-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 5)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 5)","ValueMeaning":{"publicId":"3597212","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 5)","longName":"3597212","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DF98-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DFB1-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 4)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 4)","ValueMeaning":{"publicId":"3597213","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 4)","longName":"3597213","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DFBB-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DFD4-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 3)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 3)","ValueMeaning":{"publicId":"3597214","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 3)","longName":"3597214","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-DFDE-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-DFF7-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 2)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 2)","ValueMeaning":{"publicId":"3597215","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 2)","longName":"3597215","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-E001-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-E01A-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Concurrent RT and TMZ","valueDescription":"Concurrent RT and TMZ","ValueMeaning":{"publicId":"2800760","version":"1","preferredName":"Concurrent RT and TMZ","longName":"2800760","preferredDefinition":"Concurrent RT and TMZ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BA8C9D9-215F-6A9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-E024-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"},{"value":"Adjuvant TMZ and Ipilimumab/placebo (cycle 1)","valueDescription":"Adjuvant TMZ and Ipilimumab/placebo (cycle 1)","ValueMeaning":{"publicId":"3597216","version":"1","preferredName":"Adjuvant TMZ and Ipilimumab/placebo (cycle 1)","longName":"3597216","preferredDefinition":"Adjuvant TMZ and Ipilimumab/placebo (cycle 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA8CC5B6-E02E-2A20-E040-BB89AD4370AC","latestVersionIndicator":"Yes","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA8CC5B6-E047-2A20-E040-BB89AD4370AC","beginDate":"2012-09-25","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-09-25","modifiedBy":"ONEDATA","dateModified":"2012-09-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5345B48-282B-BE91-E040-BB89AD433C8B","latestVersionIndicator":"Yes","beginDate":"2012-07-19","endDate":null,"createdBy":"GEINOZS","dateCreated":"2012-07-19","modifiedBy":"SBR","dateModified":"2014-01-24","changeDescription":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Agent treatment being reported","type":"Preferred Question Text","description":"Agent treatment being reported","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBA311A1-E3B5-6FAA-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2012-10-09","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2012-10-09","modifiedBy":"SBR","dateModified":"2014-01-24","changeDescription":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}